Next Article in Journal
Persistent Urogenital Schistosomiasis and Its Associated Morbidity in Endemic Communities within Southern Ghana: Suspected Praziquantel Resistance or Reinfection?
Previous Article in Journal
Exercise-Induced Oxygen Desaturation during the 6-Minute Walk Test
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Medical Sciences
Volume 8
Issue 1
10.3390/medsci8010009
medsci-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

A Systematic Review of the Extra-Hepatic Manifestations of Hepatitis E Virus Infection

by
Prashanth Rawla
1,*,
Jeffrey Pradeep Raj
2,
Alan Jose Kannemkuzhiyil
3,
John Sukumar Aluru
4,
Krishna Chaitanya Thandra
5 and
Mahesh Gajendran
6
1
Department of Medicine, Sovah Health, Martinsville, VA 24112, USA
2
Department of Clinical Pharmacology, Seth G.S. Medical College & King Edward Memorial Hospital, Mumbai 400012, India
3
St. Johns Medical College, St. John’s National Academy of Health Sciences, Bengaluru, Karnataka 560034, India
4
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02212, USA
5
Department of Pulmonary and Critical Care Medicine, Sentara Virginia Beach General Hospital, Virginia Beach, VA 23454, USA
6
Department of Internal Medicine, Texas Tech University Health Sciences Center El Paso, Paul L. Foster School of Medicine, El Paso, TX 79905, USA
*
Author to whom correspondence should be addressed.
Med. Sci. 2020, 8(1), 9; https://doi.org/10.3390/medsci8010009
Submission received: 4 November 2019 / Revised: 30 January 2020 / Accepted: 30 January 2020 / Published: 4 February 2020
(This article belongs to the Section Hepatic and Gastroenterology Diseases)
Browse Figure
Versions Notes

Abstract

:
Hepatitis E virus (HEV) is a non-enveloped, positive-sense, single-stranded RNA icosahedral virus belongs to the genus Orthohepevirus within the Hepeviridae family. HEV infection can be asymptomatic, or it can cause icteric or fulminant hepatitis. Off late, there have been a number of publications reporting the extra-hepatic manifestations of HEV infection, and this systematic review is aimed at summarizing the available evidence in this regard. Two independent investigators searched PubMed, PubMed Central and Embase databases using the search string “(((hepatitis E) AND (Extrahepatic OR Extra-Hepatic))) OR ((Hepatitis E) AND (Neurology OR Cardiology OR Respiratory OR Lung OR Gastrointestinal OR musculoskeletal OR immunology OR pulmonary)) Filters: Abstract availability, English language, and Human studies”. The extra-hepatic manifestations reported in each of the selected articles were classified and reported as neurological, cardiovascular, and hematological and miscellaneous manifestations. The total number of various manifestations reported in our study were n = 324. These include neurological manifestations (n = 178/324 (54.94%)), cardiovascular and hematological manifestations (n = 113/324 (34.88%)), gastro-intestinal/pancreaticobiliary manifestations (n = 24/324 (7.41%)) and other rarer manifestations involving systems such as renal (n = 4/324; 1.24%), endocrine (n = 1/324; 0.31%), dermatology (n = 1/324; 0.31%), respiratory (n = 1/324; 0.31%), muscular (n = 1/324; 0.31%) and immune system (n = 1/324; 0.31%). Thus, HEV can have extra-hepatic manifestations affecting any system of the human body. Further research is needed to elucidate the underlying pathophysiological manifestations of these extra-hepatic manifestations and to prove causal association with HEV.

1. Introduction

Hepatitis E virus (HEV) is a non-enveloped, positive-sense, single-stranded RNA icosahedral virus that belongs to the Orthohepevirus within the Hepeviridae family. Transmission of HEV can occur through the fecal-oral route by contaminated food and water, transfusion of blood, and through mother-to-child vertical transmission. Although person-to-person transmission is uncommon, patients are infectious during fecal shedding [1]. HEV is represented by one serotype and four main genotypes wherein genotypes 1 and 2 spread via the fecal–oral route and cause the epidemics, while genotypes 3 and 4 are zoonotic [2]. Genotypes 1 and 2 are endemic in many developing nations. Genotype 1 is the most common cause of acute hepatitis in Asian countries, especially in India. Genotype 2 is seen commonly in Africa and Central America, Genotype 3 is prevalent in western countries, as well as in Asia and North America, while genotype 4 is detected in Asian and European countries [3]. HEV infection is one of the most common causes of acute hepatitis globally with 20 million infections annually and an estimated 70,000 deaths attributed to genotypes 1 and 2 [4].
HEV infection can be asymptomatic, or it can cause icteric or fulminant hepatitis [5]. The seroprevalence of HEV was estimated at 6% in the USA, 11% in the UK, and 52% in the hyperendemic Toulouse region of south-west France in 2015 [6]. A more recent meta-analysis of 2018 has shown that prevalence is up to 9% in the USA, 4.2% in Brazil and up to 1% in the Mixed Caribbean [7]. Chronic HEV infection has also been reported, commonly associated with genotype 3, resulting in progressive liver failure, liver fibrosis, and cirrhosis [8]. Of late, there have been a number of publications reporting the extra-hepatic manifestations of HEV infection, both acute and chronic, mainly due to the temporal association between the infection and the extra-hepatic manifestations after excluding the other possible etiologies that may mimic the manifestations. These extra-hepatic manifestations may thus distract the physician from diagnosing HEV infection, and this systematic review is aimed at summarizing the available evidence in this regard.

2. Methods

Two independent investigators (JPR and AJK) searched PubMed, PubMed Central and Embase databases on 20th October 2018. The search string used in these databases were “(((hepatitis E) AND (Extrahepatic OR Extra-Hepatic))) OR ((Hepatitis E) AND (Neurology OR Cardiology OR Respiratory OR Lung OR Gastrointestinal OR musculoskeletal OR immunology OR pulmonary)) Filters: Abstract availability, English language, and Human studies”. Discrepancies between the two authors were adjudicated by another author (PRR). Review articles, letters to editors where abstract was not available and articles in whom the full text was not available were excluded. Finally, the extra-hepatic manifestations reported in each of the selected articles were classified and reported as neurological, cardiovascular, and hematological and miscellaneous manifestations.

3. Results

3.1. Demographics

A total of 4215 articles (n = 1141 in PubMed; n = 2321 in PubMed Central and n = 753 in Embase) were retrieved based on the search strategy. After removing duplicates, articles unrelated to the objective, conference proceedings, unavailable full-texts, and non-English reports, the final number of articles included in this systematic review was n = 66. The PRISMA (preferred reporting items for systematic reviews and meta-analyses) flow diagram is given in Figure 1.
The total number of various manifestations reported in our study were N = 324. Neurological disorder was the most common extrahepatic manifestation of hepatitis E infection, with a total of n = 178/324 (54.94%) manifestations having been reported in our review. This was followed by the cardiovascular and hematological manifestations that accounted for n = 113/324 (34.88%) manifestations. The third common system involvement was the gastro-intestinal/pancreaticobiliary system that accounted for n = 24/324 (7.41%) manifestations. Rarer manifestations involving systems such as renal (n = 4/324; 1.24%), Endocrine (n = 1/324; 0.31%), Dermatology (n = 1/324; 0.31%), respiratory (n = 1/324; 0.31%), muscular (n = 1/324; 0.31%) and immune system (n = 1/324; 0.31%) were also reported.

3.2. Neurological and Musculoskeletal Manifestations

Among the neuro-muscular manifestations, the commonly reported were neuralgic amyotrophy (n = 102/179; 56.98%) [9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24] and Guillain–Barré syndrome (n = 36/179; 20.11%) [10,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40]. The other rarer neurological manifestations that were reported include mononeuritis multiplex [10], encephalitis [11,13,39,41], cerebral ischemia [11,39], myasthenia gravis [42], polyneuromyopathy [24,43], meningo-radiculitis [10,44], epilepsy [11], encephalopathy [45], facial nerve palsy [11,46,47], encephalitic parkinsonism [48], transverse myelitis [49], peripheral neuropathy [24,39,50], vestibular neuritis [24], small fiber neuropathy [24], Myositis [51], and certain non-specific neurological symptoms like myalgias, joint pains, etc. [52,53] which are summarized in Table 1.

3.3. Cardiovascular and Hematological Manifestations

Among the cardiovascular and hematological manifestations, the commonly reported ones include cryoglobulinemia (n = 51/113; 45.13%) [55] and monoclonal gammopathy (n = 17/113; 15.04%). [24] The cardiovascular manifestations include myocarditis [56,57], cardiac arrhythmias [24], long QT syndrome [58], and Torsade’s de pointes [58]. The other hematological manifestations that were reported include anemia [59], thrombocytopenia, [24,59] lymphocytosis, [24] lymphopenia [24], leukocytosis [60], massive hemolysis [61], metabolic acidosis [60], and hematological malignancies [24] which are summarized in Table 2.

3.4. Gastrointestinal/Pancreatico-Biliary and Miscellaneous Manifestations

With regards to the gastro-intestinal/pancreaticobiliary system, pancreatitis (n = 22/24; 91.67%) [60,62,63,64,65,66,67] was the most common manifestation. One of these patients also had a pancreatic pseudocyst [66]. The other manifestation reported from this system was acalculous cholecystitis [68]. Table 3 summarizes the reports of manifestations of other systems such as endocrinology [69], dermatology [70], immunology [71], renal [60,61] and respiratory [72] whose frequencies of occurrence have been rare.

4. Discussion

In this systematic review, we have summarized the frequencies of various neurological, cardiovascular, hematological, gastrointestinal and other systemic extra-hepatic manifestations of HEV infection that have been reported in the literature. We report that neurological manifestations are more common over the other manifestations, which are followed by the hematological manifestations. However, it is clear that any body system could be affected by HEV and can present with manifestations. HEV infection is a self-limiting illness lasting a few days with symptoms of hepatitis such as jaundice, fever, nausea, vomiting, abdominal pain, anorexia, and malaise [75]. Mortality is greater in patients who are pregnant or have chronic liver disease [75]. However, chronic infection has also been reported especially with genotype-3 [75].
Various extra-hepatic manifestations of HEV have been reported from time to time, and the neurological manifestations clearly take the lead. The acute inflammatory demyelinating polyradiculoneuropathy (AIDP) is the most common variant of HEV associated GBS (Guillain-Barre syndrome) [76]. Whereas, in a vast majority of patients with neuralgic amyotrophy, the brachial plexus or the phrenic nerve was most commonly affected. These patients are thought to be genetically predisposed for an autoimmune response [77] Though the pathophysiology behind these manifestations is largely unclear, three hypotheses have been put forth [75,76,77], the first hypothesis being the presence of HEV quasi-species with the ability to infect neurologic tissues [75,77]. This is supported by the fact that HEV RNA had been isolated from the cerebrospinal fluid (CSF) of patients, and it was found to be different from that of the ones seen in the serum at the same time point, suggesting the presence of certain neurotropic variants [52]. However, this has not always been the case wherein HEV RNA has not been isolated from the CSF [38]. The second hypothesis being the ability of the virus to acquire host RNA sequences, thereby the property to infect multiple cell types including the CNS [77]. The third one being the property of some strains to produce certain antigens which in turn leads to autoimmune inflammatory polyneuropathy via molecular mimicry [76,77]. In patients with neurological disorders especially peripheral nerve involvement and concurrent liver enzyme elevation it is recommended that clinicians consider the possibility of HEV infection.
The most striking hematological manifestation is cryoglobulinemia, and the pathophysiology is largely unknown. One hypothesis is that there may be an increased expression of serum B cell-activating factor (BAFF), a tumor necrosis factor (TNF)-α family member required for B cell survival that has been documented in certain autoimmune diseases and hepatitis C infection. Thus, cryoglobulinemia has been reported in conjunction with other autoimmune or inflammatory disorders [78], especially in several other viral hepatitis including hepatitis C virus [79]. Thus, for the association between cryoglobulinemia and HEV, it is possible that either HEV causes cryoglobulinemia whose mechanism is currently unknown, or pre-existing cryoglobulinemia weakens the immune system of the patient who subsequently acquires HEV infection [24]. The same could be true for the hematological malignancies, as well [79]. Cryoglobulinemia, in turn, can cause renal injury and glomerulonephritis [80]. Though thrombocytopenia could be due to autoimmune causes as in other viral infections [81]. the changes in lymphocyte and platelet counts are most likely to be non-specific, found following inflammatory stimuli as these changes had no clinical consequences [24].
With regards to pancreatitis, it was once thought to be mostly associated with fulminant hepatitis, but of late, this dictum has been proven to be wrong as more and more pancreatitis has been reported in patients without fulminant hepatitis [81]. Like other extrahepatic manifestations, the underlying mechanism is largely unknown, and there are a few hypotheses. Some of these include biliary sludging in the early phase of viral illness, the development of edema of the hepatopancreatic ampulla (ampulla of Vater) and a resultant obstruction to the pancreatic fluid outflow, direct inflammation and destruction of pancreatic acinar cell by the virus, release of lysosomal enzymes from the inflamed liver along with the activation of trypsinogen to trypsin and rarely, intrapancreatic hemorrhage due to hypoprothrombinemia or disseminated intravascular coagulation resulting in pancreatic damage and subsequent pancreatitis [81]. Thus, any patient with HEV and abdominal pain out of proportion should be evaluated for acute pancreatitis and conservatively managed [81]. We have also reported a large number of other manifestations, which are much rarer and thus would require more case studies/reports and further research to prove their association with HEV.
Our study, however, has a few limitations. Our main limitation is that this is a review of studies indexed in just three databases and there is a likelihood that we have missed information that was published in non-indexed journals/conference proceedings.

5. Conclusions

In this systematic review, we have made an attempt to summarize the plethora of extra-hepatic manifestations of HEV that have been reported as either case reports, case series, retrospective/prospective observational studies. These manifestations could affect any of the systems in our human body. We report that neurological manifestations (GBS or neuralgic amyotrophy) are the most common extrahepatic manifestations followed by cryoglobulinemia and other inconsequential hematological changes. Acute pancreatitis like in any other viral hepatitis is seen associated with HEV also. Further research is needed to elucidate the underlying pathophysiological manifestations of these extra-hepatic manifestations and to prove causal association with HEV.

Author Contributions

Conception and design: P.R., J.P.R., A.J.K.; analysis and interpretation, drafting and critical revision of the article: P.R., J.P.R., A.J.K., K.C.T., J.S.A., M.G.; final approval of the article: P.R., J.P.R., A.J.K., K.C.T., J.S.A., M.G. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding

Conflicts of Interest

The other authors declare no conflict of interest.

References

  1. Debing, Y.; Moradpour, D.; Neyts, J.; Gouttenoire, J. Update on hepatitis E virology: Implications for clinical practice. J. Hepatol. 2016, 65, 200–212. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Meng, X.-J. Zoonotic and Foodborne Transmission of Hepatitis E Virus. Semin. Liver Dis. 2013, 33, 41–49. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Tengan, F.M.; Figueiredo, G.M.; Nunes, A.K.S.; Manchiero, C.; Dantas, B.P.; Magri, M.C.; Prata, T.V.G.; Nascimento, M.; Mazza, C.C.; Abdala, E.; et al. Seroprevalence of hepatitis E in adults in Brazil: a systematic review and meta-analysis. Infect. Dis. Poverty 2019, 8, 3. [Google Scholar] [CrossRef]
  4. Rein, D.B.; Stevens, G.A.; Theaker, J.; Wittenborn, J.S.; Wiersma, S.T. The global burden of hepatitis E virus genotypes 1 and 2 in 2005. Hepatol. 2012, 55, 988–997. [Google Scholar] [CrossRef] [PubMed]
  5. Bazerbachi, F.; Haffar, S. Acute fulminant vs. acute-on-chronic liver failure in hepatitis E: Diagnostic implications. Infect. Dis. 2015, 47, 112. [Google Scholar] [CrossRef] [PubMed]
  6. Bazerbachi, F.; Haffar, S.; Garg, S.K.; Lake, J.R. Extra-hepatic manifestations associated with hepatitis E virus infection: A comprehensive review of the literature. Gastroenterol. Rep. 2015, 4, 1–15. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  7. Horvatits, T.; Ozga, A.-K.; Westhölter, D.; Hartl, J.; Manthey, C.F.; Lütgehetmann, M.; Rauch, G.; Kriston, L.; Lohse, A.W.; Bendall, R.; et al. Hepatitis E seroprevalence in the Americas: A systematic review and meta-analysis. Liver Int. 2018, 38, 1951–1964. [Google Scholar] [CrossRef]
  8. Kamar, N.; Izopet, J.; Dalton, H.R. Chronic hepatitis e virus infection and treatment. J. Clin. Exp. Hepatol. 2013, 3, 134–140. [Google Scholar] [CrossRef] [Green Version]
  9. Avila, J.D.; Lacomis, D.; Lam, E.M. Neuralgic Amyotrophy Associated with Hepatitis E Virus Infection. J. Clin. Neuromuscul. Dis. 2016, 18, 96–100. [Google Scholar] [CrossRef]
  10. Perrin, H.B.; Cintas, P.; Abravanel, F.; Gerolami, R.; D’Alteroche, L.; Raynal, J.-N.; Alric, L.; Dupuis, E.; Prudhomme, L.; Vaucher, E.; et al. Neurologic Disorders in Immunocompetent Patients with Autochthonous Acute Hepatitis E. Emerg. Infect. Dis. 2015, 21, 1928–1934. [Google Scholar] [CrossRef] [Green Version]
  11. Dalton, H.R.; Van Eijk, J.J.; Cintas, P.; Madden, R.G.; Jones, C.; Webb, G.W.; Norton, B.; Pique, J.; Lutgens, S.; Devooght-Johnson, N.; et al. Hepatitis E virus infection and acute non-traumatic neurological injury: A prospective multicentre study. J. Hepatol. 2017, 67, 925–932. [Google Scholar] [CrossRef] [PubMed]
  12. Dartevel, A.; Colombe, B.; Bosseray, A.; Larrat, S.; Sarrot-Reynauld, F.; Belbezier, A.; Lagrange, E.; Bouillet, L. Hepatitis E and neuralgic amyotrophy: Five cases and review of literature. J. Clin. Virol. 2015, 69, 156–164. [Google Scholar] [CrossRef] [PubMed]
  13. Deroux, A.; Brion, J.; Hyerle, L.; Belbézier, A.; Vaillant, M.; Mosnier, E.; Larrat, S.; Morand, P.; Pavese, P. Association between hepatitis E and neurological disorders: Two case studies and literature review. J. Clin. Virol. 2014, 60, 60–62. [Google Scholar] [CrossRef] [PubMed]
  14. Fong, F.; Illahi, M. Neuralgic amyotrophy associated with hepatitis E virus. Clin. Neurol. Neurosurg. 2009, 111, 193–195. [Google Scholar] [CrossRef] [PubMed]
  15. Fritz, M.; Berger, B.; Schemmerer, M.; Endres, D.; Wenzel, J.J.; Stich, O.; Panning, M. Pathological Cerebrospinal Fluid Findings in Patients with Neuralgic Amyotrophy and Acute Hepatitis E Virus Infection. J. Infect. Dis. 2018, 217, 1897–1901. [Google Scholar] [CrossRef]
  16. Jones, K.; Van Eijk, J.; Ripellino, P.; Madden, R.; Herrod, J.; Lissmann, R.; Webb, G.; Abdelrahim, M.; Ashraf, H.; Almasri, O.; et al. Clinical phenotype and outcome of hepatitis E virus associated neuralgic amyotrophy; an international retrospective comparative cohort study. J. Hepatol. 2017, 66, S59. [Google Scholar] [CrossRef]
  17. Azofra, M.S.; Portales, M.R.; Laureiro, L.T.; García-Samaniego, J.; Sanz, P.M. Hepatitis E virus in neurological disorders: a case of Parsonage-Turner syndrome. Revista Española de Enfermedades Digestivas 2018, 110, 402–403. [Google Scholar]
  18. Scanvion, Q.; Perez, T.; Cassim, F.; Outteryck, O.; Lanteri, A.; Hatron, P.-Y.; Lambert, M.; Morell-Dubois, S. Neuralgic amyotrophy triggered by hepatitis E virus: a particular phenotype. J. Neurol. 2017, 264, 770–780. [Google Scholar] [CrossRef]
  19. Silva, M.; Wicki, B.; Tsouni, P.; Cunningham, S.; Doerig, C.; Zanetti, G.; Aubert, V.; Sahli, R.; Moradpour, D.; Kuntzer, T. Hepatitis E virus infection as a direct cause of neuralgic amyotrophy. Muscle Nerve 2016, 54, 325–327. [Google Scholar] [CrossRef]
  20. Swinnen, B.; Boeynaems, S.; Schrooten, M.; Saegeman, V.; Claeys, K.G.; Van Damme, P. Anterior interosseous mononeuropathy associated with HEV infection. Neurol. Neuroimmunol. Neuroinflamm. 2018, 5, 1–3. [Google Scholar] [CrossRef] [Green Version]
  21. Theochari, E.; Vincent-Smith, L.; Ellis, C. Neuralgic amyotrophy complicating acute hepatitis E infection: a rare association. BMJ Case Rep. 2015, 2015, 2014–2016. [Google Scholar] [CrossRef]
  22. Van Eijk, J.J.; Madden, R.G.; Van Der Eijk, A.A.; Hunter, J.G.; Reimerink, J.H.; Bendall, R.P.; Pas, S.D.; Ellis, V.; Van Alfen, N.; Beynon, L.; et al. Neuralgic amyotrophy and hepatitis E virus infection. Neurol. 2014, 82, 498–503. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Velay, A.; Kack-Kack, W.; Abravanel, F.; Lhomme, S.; Leyendecker, P.; Kremer, L.; Chamouard, P.; Izopet, J.; Fafi-Kremer, S.; Barth, H. Parsonage-Turner syndrome due to autochthonous acute genotype 3f hepatitis E virus infection in a nonimmunocompromised 55-year-old patient. J. NeuroVirology 2017, 23, 615–620. [Google Scholar] [CrossRef] [PubMed]
  24. Woolson, K.L.; Forbes, A.; Vine, L.; Beynon, L.; McElhinney, L.; Panayi, V.; Hunter, J.G.; Madden, R.G.; Glasgow, T.; Kotecha, A.; et al. Extra-hepatic manifestations of autochthonous hepatitis E infection. Aliment. Pharmacol. Ther. 2014, 40, 1282–1291. [Google Scholar] [CrossRef] [PubMed]
  25. Al-Saffar, A.; Al-Fatly, B. Acute Motor Axonal Neuropathy in Association with Hepatitis E. Front. Neurol. 2018, 9, 1–4. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  26. Bandyopadhyay, D.; Ganesan, V.; Choudhury, C.; Kar, S.S.; Karmakar, P.; Choudhary, V.; Banerjee, P.; Bhar, D.; Hajra, A.; Layek, M.; et al. Two Uncommon Causes of Guillain-Barré Syndrome: Hepatitis E and Japanese Encephalitis. Case Rep. Neurol. Med. 2015, 2015, 1–4. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  27. Choudhary, M.C.; Bajpai, V.; Anand, L.; Gupta, E. Guillain-Barré syndrome in a patient of acute Hepatitis E virus infection associated with genotype 1: Case report and literature review. Intractable Rare Dis. Res. 2019, 8, 43–47. [Google Scholar]
  28. Cronin, S.; McNicholas, R.; Kavanagh, E.; Reid, V.; O’Rourke, K. Anti-glycolipid GM2-positive Guillain-Barre syndrome due to hepatitis E infection. Ir. J. Med. Sci. 2011, 180, 255–257. [Google Scholar] [CrossRef]
  29. Fukae, J.; Tsugawa, J.; Ouma, S.; Umezu, T.; Kusunoki, S.; Tsuboi, Y. Guillain–Barré and Miller Fisher syndromes in patients with anti-hepatitis E virus antibody: a hospital-based survey in Japan. Neurol. Sci. 2016, 37, 1849–1851. [Google Scholar] [CrossRef]
  30. Higuchi, M.; Fukae, J.; Tsugawa, J.; Ouma, S.; Takahashi, K.; Mishiro, S.; Tsuboi, Y. Dysgeusia in a Patient with Guillain-Barré Syndrome Associated with Acute Hepatitis E: A Case Report and Literature Review. Intern. Med. 2015, 54, 1543–1546. [Google Scholar] [CrossRef] [Green Version]
  31. Lei, J.; Tian, Y.; Luo, H.; Chen, Z.; Peng, F. Guillain–Barre Syndrome Following Acute Co-Super-Infection of Hepatitis E Virus and Cytomegalovirus in a Chronic Hepatitis B Virus Carrier. J. Med. Virol. 2017, 19, 368–372. [Google Scholar] [CrossRef] [PubMed]
  32. Loly, J.P.; Rikir, E.; Seivert, M.; Legros, E.; Defrance, P.; Belaiche, J.; Moonen, G.; Delwaide, J. Guillain-Barré syndrome following hepatitis E. World J. Gastroenterol. 2009, 15, 1645–1647. [Google Scholar] [CrossRef]
  33. Maurissen, I.; Jeurissen, A.; Strauven, T.; Sprengers, D.; De Schepper, B. First case of anti-ganglioside GM1-positive Guillain-Barré syndrome due to hepatitis e virus infection. Infection 2012, 40, 323–326. [Google Scholar] [CrossRef] [PubMed]
  34. Salim, O.J.; Davidson, A.; Li, K.; Leach, J.P.; Heath, C. Brainstem encephalitis and acute polyneuropathy associated with hepatitis E infection. BMJ Case Rep. 2017, 2017, 2–5. [Google Scholar] [CrossRef] [PubMed]
  35. Santos, L.; Mesquita, J.; Pereira, N.R.; Lima-Alves, C.; Serrao, R.; Figueiredo, P.; Reis, J.; Simões, J.; Nascimento, M.; Sarmento, A. Acute hepatitis E complicated by Guillain-Barré syndrome in Portugal, December 2012—A case report. Eurosurveillance 2013, 18, 20563. [Google Scholar] [CrossRef] [PubMed]
  36. Scharn, N.; Ganzenmueller, T.; Wenzel, J.J.; Dengler, R.; Heim, A.; Wegner, F. Guillain-Barré syndrome associated with autochthonous infection by hepatitis E virus subgenotype 3c. Infection 2014, 42, 171–173. [Google Scholar] [CrossRef] [PubMed]
  37. Stevens, O.; Poesen, K.; Saegeman, V.; Claeys, K.G.; Van Damme, P. Diagnostic Challenges and Clinical Characteristics of Hepatitis E Virus–Associated Guillain-Barré Syndrome. JAMA Neurol. 2017, 74, 26. [Google Scholar] [CrossRef]
  38. Berg, B.V.D.; Van Der Eijk, A.A.; Pas, S.D.; Hunter, J.; Madden, R.G.; Tio-Gillen, A.P.; Dalton, H.R.; Jacobs, B.C. Guillain-Barre syndrome associated with preceding hepatitis E virus infection. Neurol. 2014, 82, 491–497. [Google Scholar] [CrossRef]
  39. Wang, Y.; Wang, S.; Wu, J.; Jiang, Y.; Zhang, H.; Li, S.; Liu, H.; Yang, C.; Tang, H.; Guo, N.; et al. Hepatitis E virus infection in acute non-traumatic neuropathy: A large prospective case-control study in China. EBioMedicine 2018, 36, 122–130. [Google Scholar] [CrossRef] [Green Version]
  40. Zheng, X.; Yu, L.; Xu, Q.; Gu, S.; Tang, L. Guillain-Barre syndrome caused by hepatitis E infection: Case report and literature review. BMC Infect. Dis. 2018, 18, 50. [Google Scholar] [CrossRef]
  41. Murkey, J.A.; Chew, K.W.; Carlson, M.; Shannon, C.L.; Sirohi, D.; Sample, H.A.; Wilson, M.R.; Vespa, P.; Humphries, R.M.; Miller, S.; et al. Hepatitis E Virus-Associated Meningoencephalitis in a Lung Transplant Recipient Diagnosed by Clinical Metagenomic Sequencing. Open Forum Infect. Dis. 2017, 4, ofx121. [Google Scholar] [CrossRef] [PubMed]
  42. Belbezier, A.; Deroux, A.; Sarrot-Reynauld, F.; Larrat, S.; Bouillet, L. Myasthenia Gravis Associated with Acute Hepatitis E Infection in Immunocompetent Woman. Emerg. Infect. Dis. 2014, 20, 908–910. [Google Scholar] [CrossRef] [PubMed]
  43. Belliere, J.; Abravanel, F.; Nogier, M.B.; Martinez, S.; Cintas, P.; Lhomme, S.; Lavayssière, L.; Cointault, O.; Faguer, S.; Izopet, J.; et al. Transfusion-acquired hepatitis E infection misdiagnosed as severe critical illness polyneuromyopathy in a heart transplant patient. Transpl. Infect. Dis. 2017, 19, e12784. [Google Scholar] [CrossRef]
  44. Despierres, L.-A.; Kaphan, E.; Shahram Attarian, S.C.-B.; Pelletier, J.; Pouget, J.; Motte, A.; Charrel, R.; Gerolami, R.; Colson, P. Neurologic Disorders and Hepatitis E, France, 2010. J. Infect. 2011, 17, 1510–1513. [Google Scholar]
  45. A De Vries, M.; A Samijn, J.P.; De Man, R.; Boots, J.M.M. Hepatitis E-associated encephalopathy in a renal transplant recipient. BMJ Case Rep. 2014, 2014, 1–4. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  46. Jha, A.K.; Nijhawan, S.; Nepalia, S.; Suchismita, A. Association of Bell’s Palsy with Hepatitis E Virus Infection: A Rare Entity. J. Clin. Exp. Hepatol. 2012, 2, 88–90. [Google Scholar] [CrossRef] [Green Version]
  47. Yazaki, Y.; Sugawara, K.; Honda, M.; Ohnishi, H.; Nagashima, S.; Takahashi, M.; Okamoto, H. Characteristics of 20 Patients with Autochthonous Acute Hepatitis E in Hokkaido, Japan: First Report of Bilateral Facial Palsy Following the Infection with Genotype 4 Hepatitis E Virus. Tohoku J. Exp. Med. 2015, 236, 263–271. [Google Scholar] [CrossRef] [Green Version]
  48. Pasha, S.A.; Pasha, S.A.; Suhasini, T.; Rao, D.A. Hepatitis E Virus-Associated Acute Encephalitic Parkinsonism. J. Assoc. Physicians India 2018, 66, 87–88. [Google Scholar]
  49. Sarkar, P.; Morgan, C.; Ijaz, S. Transverse myelitis caused by hepatitis E: previously undescribed in adults. BMJ Case Rep. 2015, 2015, 2014–2016. [Google Scholar] [CrossRef] [Green Version]
  50. Bennett, S.; Li, K.; Gunson, R.N. Hepatitis E virus infection presenting with paraesthesia. Scott. Med J. 2015, 60, e27–e29. [Google Scholar] [CrossRef]
  51. Mengel, A.M.; Stenzel, W.; Meisel, A.; Büning, C. Hepatitis E-induced severe myositis. Muscle Nerve 2016, 53, 317–320. [Google Scholar] [CrossRef]
  52. Kamar, N.; Izopet, J.; Cintas, P.; Garrouste, C.; Uro-Coste, E.; Cointault, O.; Rostaing, L. Hepatitis e virus-induced neurological symptoms in a kidney-transplant patient with chronic hepatitis: Case report. Am. J. Transpl. 2010, 10, 1321–1324. [Google Scholar] [CrossRef] [PubMed]
  53. Blayney, L.; Morrish, P. Acute hepatitis E infection as a cause of unexplained neurological symptoms. BMJ Case Rep. 2018, 2018, 9–11. [Google Scholar] [CrossRef] [PubMed]
  54. Alpers, E.C.; Smith, K.D. Cryoglobulinemia and renal disease. Curr. Opin. Nephrol. Hypertens. 2008, 17, 243–249. [Google Scholar] [CrossRef] [PubMed]
  55. Marion, O.; Abravanel, F.; Del Bello, A.; Esposito, L.; Lhomme, S.; Puissant-Lubrano, B.; Alric, L.; Faguer, S.; Izopet, J.; Kamar, N. Hepatitis E virus-associated cryoglobulinemia in solid-organ-transplant recipients. Liver Int. 2018, 38, 2178–2189. [Google Scholar] [CrossRef]
  56. Premkumar, M.; Rangegowda, D.; Vashishtha, C.; Bhatia, V.; Khumuckham, J.S.; Kumar, B. Acute Viral Hepatitis E Is Associated with the Development of Myocarditis. Case Rep. Hepatol. 2015, 2015, 1–6. [Google Scholar] [CrossRef]
  57. Dougherty, T.; Bashir, S.; Adam, M.K.J.; Borum, M. Acute Myopericarditis due to Hepatitis E Virus Infection: The First Reported Case in the Western Hemisphere. J. Gastrointest. Dig. Syst. 2016, 6, 5–6. [Google Scholar] [CrossRef]
  58. Aiqin, Z.; Dongming, X.; Kejun, T.; Yun, Z. Long Qt Syndrome and Torsades De Points in a Patient with Acute Hepatitis E Virus Infection: An Unusual Case. Hear. 2012, 98, E222–E223. [Google Scholar] [CrossRef] [Green Version]
  59. Kishore, J.; Sen, M. Parvovirus B19-induced Thrombocytopenia and Anemia in a Child with Fatal Fulminant Hepatic Failure Coinfected with Hepatitis A and E Viruses. J. Trop. Pediatr. 2009, 55, 335–337. [Google Scholar] [CrossRef] [Green Version]
  60. Saarwaani, V.; Prabhu, M.; Weena, S.; Saraschandra, V. Multiorgan Dysfunction from Hepatitis E infection. Crit. Care Med. 2017, 46, 240. [Google Scholar]
  61. Karki, P.; Malik, S.; Mallick, B.; Sharma, V.; Rana, S.S. Massive Hemolysis Causing Renal Failure in Acute Hepatitis E Infection. JCTH 2016, 4, 345–347. [Google Scholar] [PubMed] [Green Version]
  62. Deniel, C.; Coton, T.; Brardjanian, S.; Guisset, M.; Nicand, E.; Simon, F. Acute pancreatitis: A rare complication of acute hepatitis E. J. Clin. Virol. 2011, 51, 202–204. [Google Scholar] [CrossRef] [PubMed]
  63. Mithun, R.; Kumar, K.; Ghoshal , U.C.; Saraswat, V.A.; Aggarwal, R.; Mohindra, S. Acute hepatitis E-associated acute pancreatitis a single center experience and literature review. Pancreas 2015, 44, 1320–1322. [Google Scholar]
  64. Peter, J.; Stallmach, A.; Tannapfel, A.; Bruns, T. Acute-on-Chronic Liver Failure with Complicating Pancreatitis After Autochthonous Hepatitis E Infection. Zahedan J. Res. Med Sci. 2017, 17, 1–4. [Google Scholar] [CrossRef]
  65. Sinha, S.; Jha, R.; Lakhtakia, S.; Narayan, G. Acute pancreatitis following kidney transplantation—Role of viral infections. Clin. Transplant. 2003, 17, 32–36. [Google Scholar] [CrossRef]
  66. Somani, S.K.; Ghosh, A.; Awasthi, G. Severe acute pancreatitis with pseudocyst bleeding due to hepatitis e virus infection. Clin. J. Gastroenterol. 2009, 2, 39–42. [Google Scholar] [CrossRef]
  67. Thakur, A.; Basu, P.P. Acute Non-Fulminant Viral Hepatitis E Presenting with Acute Pancreatitis—An Unusual Presentation. MJMS 2017, 24, 102–105. [Google Scholar] [CrossRef]
  68. Fujioka, K.; Nishimura, T.; Seki, M.; Kinoshita, M.; Mishima, N.; Irimajiri, S.; Yamato, M. Genotype 1 hepatitis E virus infection with acute acalculous cholecystitis as an extrahepatic symptom: a case report. Trop. Med. Heal. 2016, 44, 18. [Google Scholar] [CrossRef] [Green Version]
  69. Dumoulin, F.L.; Liese, H. Acute hepatitis E virus infection and autoimmune thyroiditis: yet another trigger? BMJ Case Rep. 2012, 2012, 2011–2012. [Google Scholar] [CrossRef] [Green Version]
  70. Mallet, V.; Bruneau, J.; Zuber, J.; Alanio, C.; Leclerc-Mercier, S.; Roque-Afonso, A.M.; Kraft, A.R.M.; Couronné, L.; Roulot, D.; Wedemeyer, H.; et al. Hepatitis E virus-induced primary cutaneous CD30(+) T cell lymphoproliferative disorder. J. Hepatol. 2017, 67, 1–26. [Google Scholar] [CrossRef]
  71. Hillebrandt, K.H.; Arsenic, R.; Hofmann, J.; Eurich, D.; Gül, S.; Strücker, B.; Sauer, I.M.; Pratschke, J.; Stockmann, M.; Raschzok, N. Acute Graft Dysfunction 17 Years After Liver Transplant: A Challenging Clinical and Histologic Manifestation of Hepatitis E. Exp. Clin. Transplant. 2018, 16, 348–351. [Google Scholar] [PubMed]
  72. Del Bello, A.; Guilbeau-Frugier, C.; Josse, A.-G.; Rostaing, L.; Izopet, J.; Kamar, N. Successful treatment of hepatitis E virus-associated cryoglobulinemic membranoproliferative glomerulonephritis with ribavirin. Transpl. Infect. Dis. 2015, 17, 279–283. [Google Scholar] [CrossRef] [PubMed]
  73. Guinault, D.; Ribes, D.; Delas, A.; Milongo, D.; Abravanel, F.; Puissant-Lubrano, B.; Izopet, J.; Kamar, N. Hepatitis E Virus–Induced Cryoglobulinemic Glomerulonephritis in a Nonimmunocompromised Person. Am. J. Kidney Dis. 2016, 67, 660–663. [Google Scholar] [CrossRef]
  74. Kumar, K.; Kumar, H.K.; Manjunath, V.; Umesh, L.; Kj, K.; Hc, K.K.; Vg, M.; L, U. Pleural effusion: A rare complication of co-infection of hepatitis A and hepatitis E. Ann. Trop. Med. Public Heal. 2012, 5, 532. [Google Scholar] [CrossRef]
  75. Kamar, N.; Abravanel, F.; Lhomme, S.; Rostaing, L.; Izopet, J. Hepatitis E virus: Chronic infection, extra-hepatic manifestations, and treatment. Clin. Res. Hepatol Gastroenterol 2014, 39, 1–8. [Google Scholar] [CrossRef] [PubMed]
  76. McLean, B.N.; Gulliver, J.; Dalton, H.R. Hepatitis E virus and neurological disorders. Pr. Neurol. 2017, 17, 282–288. [Google Scholar] [CrossRef]
  77. Dalton, H.R.; Kamar, N.; Van Eijk, J.J.J.; Mclean, B.N.; Cintas, P.; Bendall, R.P.; Jacobs, B.C. Hepatitis E virus and neurological injury. Nat. Rev. Neurol. 2016, 12, 77–85. [Google Scholar] [CrossRef]
  78. Brown, L.M.; Gridley, G.; Check, D.; Landgren, O. Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood 2008, 111, 3388–3394. [Google Scholar] [CrossRef] [Green Version]
  79. Maso, L.D.; Franceschi, S. Hepatitis C Virus and Risk of Lymphoma and Other Lymphoid Neoplasms: A Meta-analysis of Epidemiologic Studies. Cancer Epidemiol. Biomark. Prev. 2006, 15, 2078–2085. [Google Scholar] [CrossRef] [Green Version]
  80. Shenoy, R.; Nair, S.; Kamath, N. Thrombocytopenia in hepatitis A--An atypical presentation. J. Trop. Pediatr. 2004, 50, 241–244. [Google Scholar] [CrossRef] [Green Version]
  81. Ji, S.B.; Lee, S.S.; Jung, H.C.; Kim, H.J.; Kim, H.J.; Kim, T.H.; Jung, W.T.; Lee, O.J.; Song, D.H. A Korean patient with Guillain-Barré syndrome following acute hepatitis E whose cholestasis resolved with steroid therapy. Clin. Mol. Hepatol. 2016, 22, 396–399. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Medsci 08 00009 g001 550
Figure 1. PRISMA diagram.
Figure 1. PRISMA diagram.
Medsci 08 00009 g001
Table
Table 1. Extra-hepatic neurological and musculoskeletal manifestations of hepatitis E infection.
Table 1. Extra-hepatic neurological and musculoskeletal manifestations of hepatitis E infection.
S. NoDisorderFirst Author (Year, Study Design)Number of Patients
1Guillain–Barré syndromeAl-Saffar (2018, CR) [25], Bandyopadhyay (2015, CR) [26], Blasco-Perin * (2015, RS) [10], Choudhary (2019, CR) [27], Cronin (2011, CR) [28], Fukae * (2016, CC) [29], Higuchi (2015, CR) [30], Ji (2016, CR) [54], Lei (2017, CR) [31], Loly (2009, CR) [32], Maurissen (2012, CR) [33], Salim (2017, CR) [34], Santos (2012, CR) [35], Scharn (2014, CR) [36], Stevens (2015, RS) [37], Van Den Berg (2014, CC) [38], Wang (2018, CC) [39], Woolson (2014, RS) [24], Zheng (2018, CR) [40].36
2Neuralgic amyotrophy (Parsonage Turner syndrome/Brachial neuritis)Avila (2016, CR) [9], Blasco-Perin (2015, RS) [10], Dalton (2017, CSS) [11]. Dartevel (2015, CS) [12], Deroux (2014, CS) [13], Fong (2009, CR) [14], Frtiz (2018, CC) [15], Jones (2017, RS) [16], Sanchez-Azofra (2018, CR) [17], Scanvion (2017, CR) [18], Silva (2016, CR) [19], Swinnen # (2018, CR) [20], Theochari (2015, CR) [21], Van Eijk (2014, Cohort) [22], Velay (2017, CR) [23], Woolson (2014, RS) [24].102
3Myasthenia gravisBelbeizer (2014, CR) [42]1
4PolyneuromyopathyBelliere (2017, CR), [43] Woolson (2014, RS) [24]2
5Mononeuritis multiplexBlasco-Perin (2015, RS) [10]6
6Meningo-radiculitisBlasco-Perin (2015, RS), [10] Despierres (2011, CS) [44]5
7Non-specific symptomsBlayney (2018, CR), [53] Kamar (2010, CR) [52]2
8Cerebral ischemiaDalton (2017, CSS), [11] Wang (2018, CC) [39]5
9EpilepsyDalton (2017, CSS) [11]2
10EncephalitisDalton (2017, CSS) [11], Deroux (2014, CS) [13], Murkey (2017, CR) [41], Wang (2018, CC) [39]5
11Facial nerve palsyDalton (2017, CSS) [11], Jha (2012, CR) [46], Yazaki (2015, CS) [47]3
12EncephalopathyDe Vries (2014, CR) [45]1
13Encephalitic ParkinsonismPasha (2018, CR) [48]1
14Transverse myelitisSarkar (2015, CR) [49]1
15Peripheral neuropathyBennet (2015, CR) [50], Wang (2018, CC) [39], Woolson (2014, RS) [24]3
16 Vestibular neuritisWoolson (2014, RS) [24]1
17Small fiber neuropathyWoolson (2014, RS) [24]1
18MyositisMengel (2016, CR) [51]1
CR: case report; RS: retrospective study; CC: Case-Control study; CS: Case Series; CSS: cross-sectional study; * one patient each was reported to have Miller-Fiser variant of Guillain–Barré syndrome; # report of a patient with anterior interosseous mono-neuropathy.
Table
Table 2. Extra-hepatic cardiovascular and hematological manifestations of hepatitis E infection.
Table 2. Extra-hepatic cardiovascular and hematological manifestations of hepatitis E infection.
S. NoDisorderFirst Author (Year, Study Design)Number of Patients
1Cardiac Arrhythmia Woolson (2014, RS) [24]1
2Long QT Syndrome and Torsade’s de pointesAiqin (2012, CR) [58]1
3MyocarditisDougherty (2016, CR) [57], Premkumar (2015, CR) [56]2
4AnemiaKishore (2009, CR) [59]1
5ThrombocytopeniaKishore (2009, CR) [58], Woolson (2014, RS) [24]13
6LymphocytosisWoolson (2014, RS) [24]14
7LymphopeniaWoolson (2014, RS) [24]8
8LeukocytosisSaarwaani (2017, CR) [60]1
9Massive hemolysisKarki (2016, CR) [61]1
10Monoclonal gammopathyWoolson (2014, RS) [24]17
11CryoglobulinemiaMarion (2018, CC) [55]51
12Metabolic acidosisSaarwaani (2017, CR) [60]1
13Malignancies (Acute myeloid leukemia, plasmacytoma)Woolson (2014, RS) [24]2
CR: case report; RS: retrospective study; CC: case-control study.
Table
Table 3. Miscellaneous extra-hepatic manifestations of hepatitis E infection.
Table 3. Miscellaneous extra-hepatic manifestations of hepatitis E infection.
S. NoDisorderSystemFirst Author (Year, Study Design)No. of Patients
1Autoimmune Thyroiditis EndocrineDumoulin (2012, CR) [69]1
2Cutaneous T-Cell lymphoproliferative disorderDermatologyMallet (2017, CR) [70]1
3PancreatitisGastro-intestinalDeniel (2011, CR) [62], Mithun (2015, RS) [63], Peter (2017, CR) [64], Saarwaani (2017, CR) [60], Sinha (2003, CS) [65], Somani (2009, CR) [66], Thakur (2017, CR) [67]22
4Pancreatic pseudocystGastro-intestinalSomani (2009, CR) [66]1
5Acalculous cholecystitisGastro-intestinalFujioka (2016, CR) [68]1
6Acute Graft DysfunctionImmunologyHillebrandt (2018, CR) [71]1
7Acute Kidney InjuryRenalKarki (2016, CR) [61], Saarwaani (2017, CR) [60]2
8cryoglobulinemic membranoproliferative glomerulonephritisRenalDel Bello (2015, CR) [72], Guinault (2016, CR) [73]2
9Pleural EffusionRespiratoryKumar (2012, CR) [74] 1
No. of: Number of; CR: case report; RS: retrospective study; CS: case series.

Share and Cite

MDPI and ACS Style

Rawla, P.; Raj, J.P.; Kannemkuzhiyil, A.J.; Aluru, J.S.; Thandra, K.C.; Gajendran, M. A Systematic Review of the Extra-Hepatic Manifestations of Hepatitis E Virus Infection. Med. Sci. 2020, 8, 9. https://doi.org/10.3390/medsci8010009

AMA Style

Rawla P, Raj JP, Kannemkuzhiyil AJ, Aluru JS, Thandra KC, Gajendran M. A Systematic Review of the Extra-Hepatic Manifestations of Hepatitis E Virus Infection. Medical Sciences. 2020; 8(1):9. https://doi.org/10.3390/medsci8010009

Chicago/Turabian Style

Rawla, Prashanth, Jeffrey Pradeep Raj, Alan Jose Kannemkuzhiyil, John Sukumar Aluru, Krishna Chaitanya Thandra, and Mahesh Gajendran. 2020. "A Systematic Review of the Extra-Hepatic Manifestations of Hepatitis E Virus Infection" Medical Sciences 8, no. 1: 9. https://doi.org/10.3390/medsci8010009

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop